Kamada Pharmaceuticals
Manufacturing · Israel · 201-500 Employees
View Company Info for Free
Overview
Headquarters
2 Holzman Street Science Park, Rehovot, ...Phone Number
+972 89406472Website
www.kamada.comRevenue
$174.8 MillionStock Symbol
KMDAIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Kamada Pharmaceuticals
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a late-stage product pipeline. Kamada was founded in 1990 and is headquartered in Rehovot, Israel.Explore more
Kamada Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Kamada Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Kamada Pharmaceuticals has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Kamada Pharmaceuticals had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Kamada Pharmaceuticals
Kamada Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Kamada Pharmaceuticals recently announced quarterly report
Product Launch: Get notified when Kamada Pharmaceuticals launches new products
Check out if Kamada Pharmaceuticals is spiking on competitors!
Check if Kamada Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Kamada Pharmaceuticals
Find 3 more new buyers
Company Profile Activity
Activity Insights
Kamada Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Kamada Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Kamada Pharmaceuticals.
Kamada Pharmaceuticals financials insights
Gather financial insights about Kamada Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Share Placement
$25M
2022
Other Financing Round
$11.4M
Kamada Pharmaceuticals Tech Stack
A closer look at the technologies used by Kamada Pharmaceuticals
See more technologies
Most Recent Scoops
Hiring Plans
Kamada Pharmaceuticals has more open roles in Operations than it has had at any time in the past 12 months.
Hiring Plans
Hiring Plans
Kamada Pharmaceuticals has more open roles in Medical & Health than it has had at any time in the past 9 months.
Hiring Plans
Earnings
reported gross profit and gross margins for fiscal year 2025 of $76.4 million and 42% respectively, compared to $70 million and 43% respectively in fiscal year 2024. The increase in gross profit is in line with the increase in total revenues, whereas the decrease in gross margin is due to product and market sales mix.
Earnings, Finance
Earnings
reported net income of $20.2 million or $0.35 per diluted share for fiscal year 2025, a 40% increase as compared to net income of $14.5 million or $0.25 per diluted share in fiscal year 2024.
Earnings, Accounting, Financial Reporting, Finance
Earnings
Earnings, Finance
Kamada Pharmaceuticals News & Media
Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting
Findings from analyses of CMV high-risk lung transplant recipients suggest CYTOGAM use is associated with improved clinical outcomes, supporting increased CYTOGAM utilization Findings from analyses of CMV high-risk lung transplant recipients suggest CYTOGAM use is associated with improved clinical outcomes, supporting increased CYTOGAM utilizationKamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory
REHOVOT, Israel and HOBOKEN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced FDA approval of the Company’s new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory. RFFIT is the gold standard neutralizing test used to measure the level of rabies-neutralizinKamada Ltd. Q1 2026 Earnings Call Summary
Moby summary of Kamada Ltd.'s Q1 2026 earnings callKamada Q1 Earnings Call Highlights
Kamada (NASDAQ:KMDA) reiterated its full-year 2026 outlook after reporting first-quarter results that management said were in line with expectations, excluding a temporary shipment delay that shifted revenue into April. Chief Executive Officer Amir London said demand across the company’s product po
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Kamada Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a late-stage product pipeline. Kamada was founded in 1990 and is headquartered in Rehovot, Israel.... Read More
